BioSource International, Inc. to License Molecular Beacon Technology From The Public Health Research Institute of The City of New York, Inc.

Apr 02, 2001, 01:00 ET from BioSource International, Inc. from ,Public Health Research Institute of The

    CAMARILLO, Calif. and NEW YORK, April 2 /PRNewswire/ -- BioSource
 International (Nasdaq: BIOI) and The Public Health Research Institute of The
 City of New York, Inc., (PHRI) announced today that PHRI has granted BioSource
 International, Inc. a non-exclusive, world-wide license to their Molecular
 Beacons Technology in the field of life science research.  The license covers
 patented rights to PHRI's improvements in fluorescently labeled nucleic acid
 detection probes, kits and assays employing such probes.  Financial terms of
 the agreement include an up-front license fee and royalties on product sales.
 The agreement will utilize the resources at BioSource's Keystone operations,
 located in Foster City, CA, which is a highly respected manufacturer of custom
 oligonucleotides used in academic and industrial markets.
     Molecular beacons are oligonucleotide (DNA) probes that report the
 presence of specific nucleic acids in homogeneous gene amplification assays
 often used in population genetics studies, disease susceptible mapping and/or
 phenotyping.  Molecular beacons are composed of single-stranded
 oligonucleotides that contain a fluorescent dye on one end and a fluorescent
 signal quencher on the other.  In the absence of a target, molecular beacons
 form a hairpin-shaped structure that places the fluorophore adjacent to the
 quencher, preventing the emission of a fluorescent signal.  In the presence of
 a target, the molecular beacons bind to complementary sequences, forcing the
 hairpin to open, which separates the fluorophore from the quencher, generating
 a bright fluorescent signal.  The intensity of the fluorescence provides a
 direct measure of the amount of amplified gene product that is present.
 Molecular beacons can be synthesized in many different colors, utilizing a
 broad range of fluorophores, which enables multiple targets to be detected in
 the same assay.  Owing to their structure, the recognition of targets by
 molecular beacons is so specific that mutations as small as a single
 nucleotide substitution can readily be detected in applications such as allele
 discrimination and gene expression analysis.
     This licensing arrangement allows BioSource, through its Keystone
 operation to expand their capabilities in the custom and catalog
 oligonucleotide synthesis market estimated to be approximately $200 million
 and to provide leading-edge technology in quantitative PCR*, gene expression
 analysis, SNP detection and allele discrimination assays.
 
     *The PCR process is covered by patents owned by Roche Molecular Systems,
 Inc.  Use of the PCR process requires a license.  A license may be obtained
 through the purchase and use of authorized reagents and the purchase and use
 of a thermocycler supplied by Applied Biosystems or otherwise negotiating a
 license with Applied Biosystems.
 
     BioSource International, Inc. is a broad based life sciences company
 focused on providing integrated solutions in the areas of functional genomics,
 proteomics, and drug discovery through the development, manufacturing,
 marketing and distribution of unique biologically active reagent systems which
 facilitate, enable and accelerate pharmaceutical development and biomedical
 research.
 
     This press release contains statements about expected future events that
 are forward-looking and subject to risks and uncertainties.  For these
 statements, we claim the safe harbor for "forward-looking statements" within
 the meaning of the Private Securities Litigation Reform Act of 1995.  Factors
 that could cause actual results to differ and vary materially from
 expectations include, but are not limited to, our ability to expand our
 product offerings and any transition to new products, product quality and
 availability, any change in business conditions, changes in our sales strategy
 and product development plans, competitive pricing pressures, continued market
 acceptance of our products, name recognition of our products, delays in the
 development of new technology, intellectual property and proprietary rights
 may not be valid or infringe the rights of others, changes in customer buying
 patterns issues, one-time events and other important factors disclosed
 previously and from time to time our filings with the Securities and Exchange
 Commission.  These cautionary statements by us should not be construed as
 exhaustive or as any admission regarding the adequacy of disclosures made by
 us.  We cannot always predict or determine after the fact what factors would
 cause actual results to differ materially from those indicated by the
 forward-looking statements or other statements.  In addition, readers are
 urged to consider statements that include the terms "believes," "belief,"
 "expects," "plans," "objectives," "anticipates," "intends," "targets,"
 "projections," or the like to be uncertain and forward-looking.  All
 cautionary statements should be read as being applicable to all
 forward-looking statements wherever they appear.  We do not undertake any
 obligation to publicly update or revise any forward-looking statements,
 whether as a result of new information, future events or otherwise.
 
 

SOURCE BioSource International, Inc.; Public Health Research Institute of The
    CAMARILLO, Calif. and NEW YORK, April 2 /PRNewswire/ -- BioSource
 International (Nasdaq: BIOI) and The Public Health Research Institute of The
 City of New York, Inc., (PHRI) announced today that PHRI has granted BioSource
 International, Inc. a non-exclusive, world-wide license to their Molecular
 Beacons Technology in the field of life science research.  The license covers
 patented rights to PHRI's improvements in fluorescently labeled nucleic acid
 detection probes, kits and assays employing such probes.  Financial terms of
 the agreement include an up-front license fee and royalties on product sales.
 The agreement will utilize the resources at BioSource's Keystone operations,
 located in Foster City, CA, which is a highly respected manufacturer of custom
 oligonucleotides used in academic and industrial markets.
     Molecular beacons are oligonucleotide (DNA) probes that report the
 presence of specific nucleic acids in homogeneous gene amplification assays
 often used in population genetics studies, disease susceptible mapping and/or
 phenotyping.  Molecular beacons are composed of single-stranded
 oligonucleotides that contain a fluorescent dye on one end and a fluorescent
 signal quencher on the other.  In the absence of a target, molecular beacons
 form a hairpin-shaped structure that places the fluorophore adjacent to the
 quencher, preventing the emission of a fluorescent signal.  In the presence of
 a target, the molecular beacons bind to complementary sequences, forcing the
 hairpin to open, which separates the fluorophore from the quencher, generating
 a bright fluorescent signal.  The intensity of the fluorescence provides a
 direct measure of the amount of amplified gene product that is present.
 Molecular beacons can be synthesized in many different colors, utilizing a
 broad range of fluorophores, which enables multiple targets to be detected in
 the same assay.  Owing to their structure, the recognition of targets by
 molecular beacons is so specific that mutations as small as a single
 nucleotide substitution can readily be detected in applications such as allele
 discrimination and gene expression analysis.
     This licensing arrangement allows BioSource, through its Keystone
 operation to expand their capabilities in the custom and catalog
 oligonucleotide synthesis market estimated to be approximately $200 million
 and to provide leading-edge technology in quantitative PCR*, gene expression
 analysis, SNP detection and allele discrimination assays.
 
     *The PCR process is covered by patents owned by Roche Molecular Systems,
 Inc.  Use of the PCR process requires a license.  A license may be obtained
 through the purchase and use of authorized reagents and the purchase and use
 of a thermocycler supplied by Applied Biosystems or otherwise negotiating a
 license with Applied Biosystems.
 
     BioSource International, Inc. is a broad based life sciences company
 focused on providing integrated solutions in the areas of functional genomics,
 proteomics, and drug discovery through the development, manufacturing,
 marketing and distribution of unique biologically active reagent systems which
 facilitate, enable and accelerate pharmaceutical development and biomedical
 research.
 
     This press release contains statements about expected future events that
 are forward-looking and subject to risks and uncertainties.  For these
 statements, we claim the safe harbor for "forward-looking statements" within
 the meaning of the Private Securities Litigation Reform Act of 1995.  Factors
 that could cause actual results to differ and vary materially from
 expectations include, but are not limited to, our ability to expand our
 product offerings and any transition to new products, product quality and
 availability, any change in business conditions, changes in our sales strategy
 and product development plans, competitive pricing pressures, continued market
 acceptance of our products, name recognition of our products, delays in the
 development of new technology, intellectual property and proprietary rights
 may not be valid or infringe the rights of others, changes in customer buying
 patterns issues, one-time events and other important factors disclosed
 previously and from time to time our filings with the Securities and Exchange
 Commission.  These cautionary statements by us should not be construed as
 exhaustive or as any admission regarding the adequacy of disclosures made by
 us.  We cannot always predict or determine after the fact what factors would
 cause actual results to differ materially from those indicated by the
 forward-looking statements or other statements.  In addition, readers are
 urged to consider statements that include the terms "believes," "belief,"
 "expects," "plans," "objectives," "anticipates," "intends," "targets,"
 "projections," or the like to be uncertain and forward-looking.  All
 cautionary statements should be read as being applicable to all
 forward-looking statements wherever they appear.  We do not undertake any
 obligation to publicly update or revise any forward-looking statements,
 whether as a result of new information, future events or otherwise.
 
 SOURCE  BioSource International, Inc.; Public Health Research Institute of The

RELATED LINKS

http://www.biosource.com